F Gomez-Peralta1, A Lecube2, A Fernández-Mariño3, I Alonso Troncoso4, C Morales5, F M Morales-Pérez6, I Guler7, C Cadarso-Suárez7. 1. Endocrinology and Nutrition Unit, Segovia General Hospital, Segovia. 2. Endocrinology and Nutrition Unit, University Hospital Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida and CIBERDEM (CIBER de Diabetes y Enfermedades Metabólicas Asociadas, ISCIII), University of Lleida, Lleida. 3. Endocrinology Unit, Complejo Hospitalario Hospital Xeral de Vigo, Vigo. 4. Endocrinology Unit, Hospital Montecelo de Pontevedra, Pontevedra. 5. Endocrinology and Nutrition Unit, Virgen Macarena Hospital, Seville. 6. Endocrinology Unit, Hospital Universitario Infanta Cristina, Badajoz. 7. Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, A Coruña, Spain.
Abstract
AIMS: To study the response of clinical variables (HbA1c , body weight, lipid profile and blood pressure) over 24 months of liraglutide treatment in a real-world clinical setting, and to describe the evolution of HbA1c and body weight reduction in response to liraglutide treatment by employing generalized additive mixed models (GAMMs). METHODS: We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015. Demographic and clinical data were retrieved retrospectively over 24 months from electronic medical records with a median duration of observation of 7.0 (IQR 3.0-12.0) months. RESULTS: Individuals that initiated liraglutide therapy were obese (BMI 39.1 kg/m2 ), with inadequate HbA1c (68 mmol/mol [8.4%]), blood pressure and lipid levels. Upon liraglutide treatment, HbA1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually. GAMMs demonstrated that longer treatment with liraglutide was a predictor of improved HbA1c response, whereas higher baseline HbA1c , longer Type 2 diabetes duration and treatment with insulin were predictors of worse HbA1c response. Higher baseline weight, longer treatment with liraglutide and the interaction between metformin and time were predictors of improved weight response. CONCLUSIONS: In this real-world study, we showed the effectiveness of liraglutide in improving body weight, HbA1c , mean systolic and diastolic blood pressure, and lipid levels. GAMMs indicated that baseline HbA1c and weight, time of treatment with liraglutide, diabetes duration and the use of metformin or insulin are predictors of clinical response to liraglutide.
AIMS: To study the response of clinical variables (HbA1c , body weight, lipid profile and blood pressure) over 24 months of liraglutide treatment in a real-world clinical setting, and to describe the evolution of HbA1c and body weight reduction in response to liraglutide treatment by employing generalized additive mixed models (GAMMs). METHODS: We included people aged ≥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015. Demographic and clinical data were retrieved retrospectively over 24 months from electronic medical records with a median duration of observation of 7.0 (IQR 3.0-12.0) months. RESULTS: Individuals that initiated liraglutide therapy were obese (BMI 39.1 kg/m2 ), with inadequate HbA1c (68 mmol/mol [8.4%]), blood pressure and lipid levels. Upon liraglutide treatment, HbA1c , body weight, mean systolic and diastolic blood pressure, and lipid levels decreased gradually. GAMMs demonstrated that longer treatment with liraglutide was a predictor of improved HbA1c response, whereas higher baseline HbA1c , longer Type 2 diabetes duration and treatment with insulin were predictors of worse HbA1c response. Higher baseline weight, longer treatment with liraglutide and the interaction between metformin and time were predictors of improved weight response. CONCLUSIONS: In this real-world study, we showed the effectiveness of liraglutide in improving body weight, HbA1c , mean systolic and diastolic blood pressure, and lipid levels. GAMMs indicated that baseline HbA1c and weight, time of treatment with liraglutide, diabetes duration and the use of metformin or insulin are predictors of clinical response to liraglutide.
Authors: Cristina Hernández; Fernando Gómez-Peralta; Rafael Simó; Olga Simó-Servat; Marta García-Ramírez; Cristina Abreu; Sara Gómez-Rodríguez Journal: Acta Diabetol Date: 2022-08-04 Impact factor: 4.087
Authors: Eric M Bomberg; Justin R Ryder; Richard C Brundage; Robert J Straka; Claudia K Fox; Amy C Gross; Megan M Oberle; Carolyn T Bramante; Shalamar D Sibley; Aaron S Kelly Journal: Ther Adv Endocrinol Metab Date: 2019-07-27 Impact factor: 3.565